Italia markets close in 2 hours 18 minutes

Cingulate Inc. (CING)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,1200+0,0800 (+7,69%)
Alla chiusura: 04:00PM EDT
1,1284 +0,01 (+0,75%)
Dopo ore: 07:15PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,0400
Aperto1,0200
Denaro0,8280 x 200
Lettera1,2900 x 200
Min-Max giorno1,0200 - 1,1600
Intervallo di 52 settimane0,7500 - 23,4000
Volume231.208
Media Volume223.793
Capitalizzazione6,772M
Beta (5 anni mensile)-0,96
Rapporto PE (ttm)N/D
EPS (ttm)-26,0000
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A15,00
  • GlobeNewswire

    Cingulate Inc. to Present at the LD Micro Main Event XVI

    Presentation on Wednesday, October 4th at 02:30 PM PTKANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that Chairman & CEO, Shane J. Schaffer, will be presenting a company overview at the 16th annual Main Event on Wednesday, October 4th at 02:30 PM PT at

  • GlobeNewswire

    Cingulate Announces Closing of $4.0 Million Public Offering

    KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the closing of its previously announced public offering of an aggregate of 6,925,208 shares of its common stock (or common stock equivalents in lieu ther

  • GlobeNewswire

    Cingulate Announces Pricing of $4.0 Million Public Offering

    KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the pricing of its public offering of an aggregate of 6,925,208 shares of its common stock (or common stock equivalents in lieu thereof), Series A warran